Did you know? You can suggest edits to improve this peptide information.
Overview
What is Cartalax?
Cartalax (AED peptide, T-31) is a synthetic tripeptide consisting of Alanine-Glutamate-Aspartate, developed by Professor Vladimir Khavinson as part of the bioregulatory peptide family. Originally isolated from kidney tissue and found in the alpha-1 chain of type XI collagen, Cartalax has shown potential in supporting cartilage, connective tissue, and cellular regeneration through modulation of proliferation markers and apoptosis pathways.
Key Benefits
Convenient administration for joint and connective tissue support, used extensively in Russian clinical practice for degenerative conditions with established safety profile.
Mechanism of Action
Each capsule contains 0.1mg (100mcg) of AC-4 peptide complex. Specialized formulation designed to survive digestion and provide systemic bioregulatory effects.
Research Indications
Clinical Joint Support
Russian studies show benefits for osteoarthritis and osteochondrosis using 0.1mg capsules
Preventive Use
Used to prevent degenerative processes in elderly patients
Post-Fracture Recovery
Supports healing after bone and joint injuries
Research Protocols
Disclaimer
These are commonly discussed research protocols and not medical advice. Consult a healthcare provider before use.
Timing
Russian manufacturers specifically recommend taking with meals to optimize tolerance.
Peptide Interactions
How to Reconstitute
Important
Always use bacteriostatic water (BAC). Sterile technique is essential.
Take capsules with meals as directed on package
Each capsule contains 0.1mg (100mcg) of active peptide complex
Swallow whole with full glass of water
Do not open or chew capsules
Store in cool, dry place away from moisture
Follow official Russian manufacturer instructions for optimal results
Quality Indicators
Pharmaceutical packaging
Russian pharmaceutical products come in professional packaging with holographic seals
Correct capsule content
Each capsule should contain exactly 0.1mg (100mcg) of AC-4 peptide complex
Clear dosing instructions
Legitimate products include detailed Russian/English instructions specifying "with meals"
Import verification
Ensure proper import documentation for authenticity
Manufacturer compliance
Follow official Russian manufacturer timing guidelines for safety and efficacy
What to Expect
- Week 1-2: No significant changes, establishing baseline
- Week 3-4: Gradual improvement in joint comfort
- Month 2: Noticeable mobility improvements
- Month 3: Maximum therapeutic effect achieved
Side Effects & Safety
- Take with meals as directed by Russian manufacturers to optimize tolerance
- No reported side effects in Russian clinical use when taken properly
- Well-tolerated even in elderly patients
- Can be combined with conventional treatments
- No drug dependence reported
References
Neuronal Differentiation Study (2022)
Cartalax, along with other Khavinson peptides, stimulated proliferation and neurogenic differentiation of stem cells, indicating broader regenerative potential beyond connective tissue.
Bone Marrow Stem Cell Study (2021)
Cartalax influenced aging-related gene expression in bone marrow mesenchymal stem cells, potentially maintaining regenerative capacity in both proliferating and stationary phase cells.
Kidney Cell Culture Research (2020)
Demonstrated reduction in pro-apoptotic p53 expression in aging kidney cells, potentially extending cellular lifespan and maintaining tissue integrity through decreased programmed cell death.
Quick Start Guide
Community Poll
Question 1 of 10
What is your experience with this compound?
Poll Results
Loading results...
Community Insights
Self-reported by PepPedia users. Not clinical evidence. Health changes reflect all users, including those taking multiple compounds.
Was this helpful?
Your feedback helps us improve PepPedia